Société Générale — Major Shareholding Notification 2021

Jul 20, 2021

National Storage Mechanism | Additional information

RNS Number : 7971F

Societe Generale SA

20 July 2021

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.       KEY INFORMATION

Name of person dealing (Note 1)	Société Générale S.A.
Company dealt in	UDG Healthcare plc
Class of relevant security to which the dealings being disclosed relate (Note 2)	€0.05 ordinary shares
Date of dealing	19/07/2021

2.         INTERESTS AND SHORT POSITIONS

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
Number	(%)	Number	(%)
(1) Relevant securities	17,352,329	6.89	10,647	0.00
(2) Derivatives (other than options)	0	0.00	11,218,405	4.45
(3) Options and agreements to purchase/sell	0	0.00	0	0.00
Total	*17,656,711	*7.01	11,229,052	4.46

* Include the holding of 304,382 shares on borrow products

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1.       DEALINGS (Note 4)

(a)      Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit GBP (Note 5)
Purchase	270	10.7
Purchase	12	10.7
Purchase	395	10.7
Purchase	379	10.7
Purchase	205	10.7
Purchase	5,526	10.7
Purchase	20	10.7
Purchase	4,562	10.7
Purchase	586	10.71
Purchase	300	10.71
Purchase	402	10.7
Sale	436	10.72
Sale	3,070	10.72
Sale	250	10.72
Sale	29	10.71
Sale	47	10.71
Sale	295	10.72
Sale	89	10.71
Sale	48	10.71
Sale	201	10.72
Sale	282	10.72
Sale	181	10.71
Sale	199	10.71
Sale	265	10.72
Sale	226	10.7
Sale	438	10.75
Sale	494	10.72
Sale	401	10.72
Sale	426	10.75
Total Purchases	12,657
Total Sales	7,377

Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit GBP (Note 5)

(b)      Options transactions in respect of existing relevant securities

(i)       Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)

(ii)      Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)

(c)      Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

Ap21

2.       OTHER INFORMATION

Agreements, arrangements, or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred

to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached? (Note 9)                                            No

Date of disclosure	20/07/2021
Contact name	Société Générale - Disclosure team
Telephone number	+33 1 42 14 92 74
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ISEEAKXEADFFEEA